Defense from the Group A Streptococcus by Active and Passive Vaccination with the Streptococcal Hemoprotein Receptor

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2011 May 20

PMID 21592989

Citations 10

Authors

Ya-Shu Huang

Morly Fisher

Ziyad Nasrawi

Zehava Eichenbaum

Affiliations

Soon will be listed here.

Abstract

Background: The worldwide burden of the Group A Streptococcus (GAS) primary infection and sequelae is considerable, although immunization programs with broad coverage of the hyper variable GAS are still missing. We evaluate the streptococcal hemoprotein receptor (Shr), a conserved streptococcal protein, as a vaccine candidate against GAS infection.

Methods: Mice were immunized intraperitoneally with purified Shr or intranasally with Shr-expressing Lactococcus lactis. The resulting humoral response in serum and secretions was determined. We evaluated protection from GAS infection in mice after active or passive vaccination with Shr, and Shr antiserum was tested for bactericidal activity.

Results: A robust Shr-specific immunoglobulin (Ig) G response was observed in mouse serum after intraperitoneal vaccination with Shr. Intranasal immunization elicited both a strong IgG reaction in the serum and a specific IgA reaction in secretions. Shr immunization in both models allowed enhanced protection from systemic GAS challenge. Rabbit Shr antiserum was opsonizing, and mice that were administrated with Shr antiserum prior to the infection demonstrated a significantly higher survival rate than did mice treated with normal rabbit serum.

Conclusions: Shr is a promising vaccine candidate that is capable of eliciting bactericidal antibody response and conferring immunity against systemic GAS infection in both passive and active vaccination models.

Citing Articles

The Shr receptor from uses a cap and release mechanism to acquire heme-iron from human hemoglobin.

Macdonald R, Mahoney B, Soule J, Goring A, Ford J, Loo J Proc Natl Acad Sci U S A. 2023; 120(5):e2211939120.

PMID: 36693107 PMC: 9945957. DOI: 10.1073/pnas.2211939120.

Native Human Antibody to Shr Promotes Mice Survival After Intraperitoneal Challenge With Invasive Group A Streptococcus.

Chatterjee N, Huang Y, Lyles K, Morgan J, Kauvar L, Greer S J Infect Dis. 2020; 223(8):1367-1375.

PMID: 32845315 PMC: 8064040. DOI: 10.1093/infdis/jiaa540.

Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.

Herrera A, Van Hove C, Hanson M, Dale J, Tweten R, Huber V PLoS One. 2020; 15(6):e0235139.

PMID: 32574205 PMC: 7310742. DOI: 10.1371/journal.pone.0235139.

A Novel Heme Transporter from the Energy Coupling Factor Family Is Vital for Group A Streptococcus Colonization and Infections.

Chatterjee N, Cook L, Lyles K, Nguyen H, Devlin D, Thomas L J Bacteriol. 2020; 202(14).

PMID: 32393520 PMC: 7317044. DOI: 10.1128/JB.00205-20.

Modeling Pharyngeal Colonization in the Mouse.

Gogos A, Federle M Front Cell Infect Microbiol. 2019; 9:137.

PMID: 31119108 PMC: 6507483. DOI: 10.3389/fcimb.2019.00137.

References

Ardanuy C, Domenech A, Rolo D, Calatayud L, Tubau F, Ayats J . Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008). J Antimicrob Chemother. 2010; 65(4):634-43. DOI: 10.1093/jac/dkq006. View

Olive C, Sun H, Ho M, Dyer J, Horvath A, Toth I . Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis. 2006; 194(3):316-24. DOI: 10.1086/505580. View

Lancefield R . Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962; 89:307-13. View

McNeil S, Halperin S, Langley J, Smith B, Warren A, Sharratt G . Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis. 2005; 41(8):1114-22. DOI: 10.1086/444458. View

Steer A, Jenney A, Kado J, Good M, Batzloff M, Magor G . Prospective surveillance of streptococcal sore throat in a tropical country. Pediatr Infect Dis J. 2009; 28(6):477-82. DOI: 10.1097/INF.0b013e318194b2af. View

Cohen-Poradosu R, Kasper D . Group A streptococcus epidemiology and vaccine implications. Clin Infect Dis. 2007; 45(7):863-5. DOI: 10.1086/521263. View

Beall B, Facklam R, Thompson T . Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol. 1996; 34(4):953-8. PMC: 228924. DOI: 10.1128/jcm.34.4.953-958.1996. View

Dale J . Current status of group A streptococcal vaccine development. Adv Exp Med Biol. 2008; 609:53-63. DOI: 10.1007/978-0-387-73960-1_5. View

Feng L, Lin H, Ma Y, Yang Y, Zheng Y, Fu Z . Macrolide-resistant Streptococcus pyogenes from Chinese pediatric patients in association with Tn916 transposons family over a 16-year period. Diagn Microbiol Infect Dis. 2010; 67(4):369-75. DOI: 10.1016/j.diagmicrobio.2010.03.014. View

10.

Buccato S, Maione D, Rinaudo C, Volpini G, Taddei A, Rosini R . Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis. 2006; 194(3):331-40. DOI: 10.1086/505433. View

11.

Beres S, Sylva G, Barbian K, Lei B, Hoff J, Mammarella N . Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci U S A. 2002; 99(15):10078-83. PMC: 126627. DOI: 10.1073/pnas.152298499. View

12.

Carapetis J, Steer A, Mulholland E, Weber M . The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005; 5(11):685-94. DOI: 10.1016/S1473-3099(05)70267-X. View

13.

Bates C, Montanez G, Woods C, Vincent R, Eichenbaum Z . Identification and characterization of a Streptococcus pyogenes operon involved in binding of hemoproteins and acquisition of iron. Infect Immun. 2003; 71(3):1042-55. PMC: 148835. DOI: 10.1128/IAI.71.3.1042-1055.2003. View

14.

Snider L, Swedo S . PANDAS: current status and directions for research. Mol Psychiatry. 2004; 9(10):900-7. DOI: 10.1038/sj.mp.4001542. View

15.

Dale J, Baird R, Courtney H, Hasty D, Bronze M . Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J Infect Dis. 1994; 169(2):319-23. DOI: 10.1093/infdis/169.2.319. View

16.

Steer A, Magor G, Jenney A, Kado J, Good M, McMillan D . emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol. 2009; 47(8):2502-9. PMC: 2725645. DOI: 10.1128/JCM.00312-09. View

17.

Kawabata S, Kunitomo E, Terao Y, Nakagawa I, Kikuchi K, Totsuka K . Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun. 2001; 69(2):924-30. PMC: 97971. DOI: 10.1128/IAI.69.2.924-930.2001. View

18.

Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J . Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine. 2003; 22(1):87-95. DOI: 10.1016/s0264-410x(03)00528-0. View

19.

Bates C, Toukoki C, Neely M, Eichenbaum Z . Characterization of MtsR, a new metal regulator in group A streptococcus, involved in iron acquisition and virulence. Infect Immun. 2005; 73(9):5743-53. PMC: 1231137. DOI: 10.1128/IAI.73.9.5743-5753.2005. View

20.

Yokoyama Y, Harabuchi Y . Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol. 2002; 63(3):235-41. DOI: 10.1016/s0165-5876(02)00021-6. View